Equities Analysts Offer Predictions for NAMS FY2027 Earnings

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) – Equities researchers at HC Wainwright dropped their FY2027 earnings estimates for shares of NewAmsterdam Pharma in a note issued to investors on Thursday, August 6th. HC Wainwright analyst L. Egana-Gorrono now anticipates that the company will post earnings per share of $2.15 for the year, down from their previous estimate of $2.36. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.78) per share. HC Wainwright also issued estimates for NewAmsterdam Pharma’s FY2028 earnings at $3.66 EPS, FY2029 earnings at $6.84 EPS and FY2030 earnings at $7.68 EPS.

Several other research analysts also recently weighed in on the company. Jefferies Financial Group reiterated a “buy” rating and issued a $45.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. BMO Capital Markets started coverage on NewAmsterdam Pharma in a report on Monday, July 20th. They set an “outperform” rating and a $58.00 price target for the company. Royal Bank Of Canada decreased their price target on NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, NewAmsterdam Pharma presently has an average rating of “Moderate Buy” and an average target price of $49.33.

NewAmsterdam Pharma Stock Up 0.9%

NAMS opened at $27.67 on Friday. The business has a 50 day moving average price of $31.49 and a two-hundred day moving average price of $32.53. The company has a market cap of $3.23 billion, a PE ratio of -12.81 and a beta of 0.10. NewAmsterdam Pharma has a 52 week low of $22.26 and a 52 week high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its earnings results on Wednesday, August 5th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative return on equity of 34.05% and a negative net margin of 3,644.21%.The business had revenue of $3.70 million for the quarter, compared to analyst estimates of $2.83 million.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 105,000 shares of the business’s stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $30.34, for a total transaction of $3,185,700.00. Following the transaction, the chief accounting officer owned 24,353 shares in the company, valued at approximately $738,870.02. The trade was a 81.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last 90 days, insiders sold 210,000 shares of company stock worth $6,713,550. Insiders own 12.74% of the company’s stock.

Institutional Trading of NewAmsterdam Pharma

Institutional investors have recently modified their holdings of the business. Farther Finance Advisors LLC raised its position in NewAmsterdam Pharma by 4,425.0% in the fourth quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after acquiring an additional 708 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of NewAmsterdam Pharma by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after purchasing an additional 300 shares in the last quarter. KBC Group NV purchased a new stake in shares of NewAmsterdam Pharma during the 1st quarter worth $37,000. Navalign LLC acquired a new position in shares of NewAmsterdam Pharma during the 4th quarter worth $46,000. Finally, AdvisorNet Financial Inc acquired a new position in shares of NewAmsterdam Pharma during the 1st quarter worth $82,000. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.